Core One Labs Signs Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin

Seeking AlphaDec 11, 2023 17:21

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry Into the International Market

AccesswireDec 9, 2023 07:55

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio-Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

AccesswireDec 2, 2023 08:00

Core One's Akome Reveals Groundbreaking Positive Results From Its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer's and Parkinson's Disease

AccesswireAug 5, 2023 07:25

Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin From Mushroom Biomass

AccesswireAug 2, 2023 07:55

Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer's and Parkinson's Disease

AccesswireJul 29, 2023 07:25